Behjatolah Karbassi
Concepts (272)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antigens, Tumor-Associated, Carbohydrate | 15 | 2023 | 24 | 3.930 |
Why?
| Cancer Vaccines | 13 | 2022 | 78 | 2.680 |
Why?
| Peptides | 17 | 2022 | 223 | 2.620 |
Why?
| Carbohydrates | 14 | 2009 | 40 | 2.430 |
Why?
| Molecular Mimicry | 13 | 2007 | 38 | 2.060 |
Why?
| Breast Neoplasms | 12 | 2024 | 1174 | 1.750 |
Why?
| Neoplasms | 9 | 2022 | 1235 | 1.520 |
Why?
| Immunotherapy | 6 | 2022 | 238 | 1.130 |
Why?
| Epitopes, T-Lymphocyte | 6 | 2009 | 24 | 0.920 |
Why?
| HIV Envelope Protein gp120 | 4 | 2009 | 9 | 0.860 |
Why?
| Lung Neoplasms | 4 | 2014 | 606 | 0.840 |
Why?
| Antibodies, Neoplasm | 2 | 2017 | 28 | 0.830 |
Why?
| HIV-1 | 4 | 2009 | 55 | 0.830 |
Why?
| Mice, Inbred BALB C | 16 | 2011 | 304 | 0.810 |
Why?
| Antigens | 4 | 2003 | 41 | 0.790 |
Why?
| Animals | 31 | 2023 | 13187 | 0.680 |
Why?
| Epithelial-Mesenchymal Transition | 2 | 2020 | 47 | 0.670 |
Why?
| Clinical Trials, Phase I as Topic | 2 | 2017 | 25 | 0.640 |
Why?
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 828 | 0.630 |
Why?
| Vaccines, DNA | 6 | 2006 | 11 | 0.630 |
Why?
| Immunologic Surveillance | 2 | 2009 | 10 | 0.620 |
Why?
| HIV Antigens | 3 | 2006 | 9 | 0.600 |
Why?
| Epitopes | 3 | 2009 | 59 | 0.590 |
Why?
| Cell Transformation, Neoplastic | 1 | 2018 | 177 | 0.580 |
Why?
| Antineoplastic Agents | 3 | 2017 | 1171 | 0.550 |
Why?
| Immunity, Innate | 3 | 2018 | 104 | 0.550 |
Why?
| Molecular Targeted Therapy | 1 | 2017 | 119 | 0.530 |
Why?
| Neoplasm Proteins | 1 | 2018 | 322 | 0.530 |
Why?
| Mice | 20 | 2011 | 5739 | 0.520 |
Why?
| Biomimetic Materials | 1 | 2014 | 9 | 0.490 |
Why?
| Cell Hypoxia | 1 | 2015 | 82 | 0.490 |
Why?
| Epigenesis, Genetic | 1 | 2018 | 374 | 0.490 |
Why?
| Estrogen Receptor alpha | 1 | 2015 | 89 | 0.480 |
Why?
| Vaccines | 4 | 2002 | 50 | 0.460 |
Why?
| T-Lymphocytes | 7 | 2010 | 338 | 0.450 |
Why?
| Cross Reactions | 8 | 2006 | 42 | 0.450 |
Why?
| Oligosaccharides | 4 | 2007 | 33 | 0.450 |
Why?
| Amino Acid Sequence | 9 | 2006 | 585 | 0.440 |
Why?
| Sarcoma, Experimental | 2 | 2004 | 13 | 0.440 |
Why?
| Molecular Sequence Data | 9 | 2006 | 792 | 0.440 |
Why?
| Polysaccharides | 2 | 2011 | 50 | 0.430 |
Why?
| Antigens, Neoplasm | 5 | 2007 | 151 | 0.430 |
Why?
| Humans | 35 | 2024 | 49974 | 0.430 |
Why?
| AIDS Vaccines | 3 | 2009 | 8 | 0.410 |
Why?
| Plant Lectins | 2 | 2010 | 8 | 0.410 |
Why?
| Isoflavones | 1 | 2023 | 89 | 0.410 |
Why?
| Sulfotransferases | 3 | 2020 | 40 | 0.400 |
Why?
| Chondroitin Sulfates | 2 | 2011 | 13 | 0.390 |
Why?
| P-Selectin | 2 | 2011 | 32 | 0.380 |
Why?
| Soybean Proteins | 1 | 2023 | 161 | 0.380 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2007 | 116 | 0.380 |
Why?
| Fructose | 1 | 2010 | 23 | 0.370 |
Why?
| Autoantigens | 1 | 2011 | 58 | 0.370 |
Why?
| Carbon | 1 | 2010 | 54 | 0.360 |
Why?
| Adaptive Immunity | 1 | 2010 | 32 | 0.360 |
Why?
| Vaccines, Subunit | 3 | 2006 | 15 | 0.340 |
Why?
| CD4-Positive T-Lymphocytes | 3 | 2006 | 164 | 0.340 |
Why?
| Obesity | 2 | 2023 | 1113 | 0.340 |
Why?
| Drug Delivery Systems | 1 | 2010 | 138 | 0.320 |
Why?
| Carcinoma, Ductal | 1 | 2008 | 9 | 0.320 |
Why?
| Proteoglycans | 3 | 2023 | 80 | 0.310 |
Why?
| Mammary Neoplasms, Experimental | 2 | 2005 | 122 | 0.300 |
Why?
| Interferon-gamma | 4 | 2018 | 177 | 0.300 |
Why?
| Carcinoma in Situ | 1 | 2008 | 73 | 0.300 |
Why?
| Cell Line, Tumor | 6 | 2011 | 1403 | 0.290 |
Why?
| Dendritic Cells | 3 | 2005 | 133 | 0.280 |
Why?
| T-Lymphocytes, Cytotoxic | 5 | 2009 | 65 | 0.280 |
Why?
| Female | 18 | 2024 | 26472 | 0.280 |
Why?
| Concanavalin A | 2 | 2005 | 11 | 0.260 |
Why?
| HIV Infections | 1 | 2009 | 357 | 0.260 |
Why?
| Sarcoma | 1 | 2006 | 67 | 0.260 |
Why?
| Mammary Neoplasms, Animal | 1 | 2005 | 35 | 0.250 |
Why?
| Ligands | 5 | 2011 | 204 | 0.250 |
Why?
| MCF-7 Cells | 4 | 2020 | 68 | 0.250 |
Why?
| Neoplasm Metastasis | 5 | 2015 | 231 | 0.240 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2005 | 244 | 0.240 |
Why?
| Acetylglucosamine | 1 | 2004 | 6 | 0.240 |
Why?
| Histocompatibility Antigens Class I | 1 | 2004 | 44 | 0.230 |
Why?
| Combined Modality Therapy | 2 | 2017 | 637 | 0.230 |
Why?
| Immunoglobulin G | 2 | 2003 | 186 | 0.230 |
Why?
| Immunotherapy, Active | 1 | 2003 | 4 | 0.220 |
Why?
| Melanoma | 1 | 2007 | 285 | 0.220 |
Why?
| Peptide Fragments | 1 | 2004 | 215 | 0.220 |
Why?
| Peptide Library | 4 | 2005 | 16 | 0.220 |
Why?
| Autoantibodies | 2 | 2018 | 116 | 0.210 |
Why?
| Glycosylation | 3 | 2010 | 100 | 0.210 |
Why?
| Cell Proliferation | 4 | 2020 | 1007 | 0.210 |
Why?
| Antigens, Viral | 1 | 2002 | 44 | 0.200 |
Why?
| Apoptosis | 2 | 2020 | 1101 | 0.200 |
Why?
| Antibodies, Monoclonal | 5 | 2023 | 459 | 0.200 |
Why?
| Biochemistry | 1 | 2001 | 5 | 0.200 |
Why?
| Liver Neoplasms | 1 | 2005 | 326 | 0.190 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 244 | 0.190 |
Why?
| Cell Adhesion | 3 | 2006 | 158 | 0.180 |
Why?
| CHO Cells | 3 | 2006 | 120 | 0.180 |
Why?
| Carbamates | 1 | 2020 | 16 | 0.180 |
Why?
| Cricetinae | 3 | 2006 | 192 | 0.180 |
Why?
| Adjuvants, Immunologic | 2 | 2014 | 51 | 0.180 |
Why?
| Colchicine | 1 | 2020 | 28 | 0.180 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 69 | 0.170 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2020 | 89 | 0.170 |
Why?
| Neoplastic Stem Cells | 1 | 2020 | 103 | 0.170 |
Why?
| Tumor Microenvironment | 2 | 2024 | 212 | 0.160 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 92 | 0.160 |
Why?
| Anthroposophy | 1 | 2018 | 1 | 0.160 |
Why?
| Tumor Cells, Cultured | 3 | 2015 | 465 | 0.160 |
Why?
| Antibody Formation | 3 | 2003 | 54 | 0.160 |
Why?
| Gene-Environment Interaction | 1 | 2018 | 36 | 0.160 |
Why?
| Cell Division | 3 | 2006 | 292 | 0.160 |
Why?
| Immunization | 3 | 2004 | 67 | 0.150 |
Why?
| Chondroitin Sulfate Proteoglycans | 2 | 2023 | 18 | 0.150 |
Why?
| Immune Tolerance | 2 | 2009 | 96 | 0.150 |
Why?
| Plant Extracts | 1 | 2020 | 190 | 0.150 |
Why?
| Cell Movement | 4 | 2020 | 247 | 0.150 |
Why?
| Flow Cytometry | 3 | 2006 | 476 | 0.150 |
Why?
| Spleen | 3 | 2004 | 172 | 0.150 |
Why?
| Homeostasis | 1 | 2018 | 200 | 0.140 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2017 | 43 | 0.140 |
Why?
| Forecasting | 1 | 2017 | 150 | 0.130 |
Why?
| HIV Antibodies | 2 | 2006 | 10 | 0.130 |
Why?
| Models, Immunological | 2 | 2007 | 8 | 0.130 |
Why?
| Membrane Proteins | 2 | 2023 | 341 | 0.130 |
Why?
| Phenotype | 2 | 2010 | 729 | 0.130 |
Why?
| Lectins | 2 | 2006 | 14 | 0.130 |
Why?
| Interleukin-12 | 2 | 2006 | 31 | 0.130 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 56 | 0.120 |
Why?
| Coculture Techniques | 1 | 2015 | 146 | 0.120 |
Why?
| Drug Therapy | 1 | 2014 | 46 | 0.120 |
Why?
| Transforming Growth Factor beta | 1 | 2015 | 144 | 0.120 |
Why?
| Antibodies | 1 | 2014 | 154 | 0.120 |
Why?
| Adipocytes | 1 | 2015 | 121 | 0.120 |
Why?
| Vaccines, Conjugate | 2 | 2005 | 8 | 0.110 |
Why?
| Nuclear Proteins | 1 | 2015 | 242 | 0.110 |
Why?
| Cell Separation | 2 | 2005 | 89 | 0.110 |
Why?
| Rats, Zucker | 1 | 2023 | 69 | 0.110 |
Why?
| Scavenger Receptors, Class E | 1 | 2015 | 204 | 0.110 |
Why?
| Positron-Emission Tomography | 1 | 2014 | 295 | 0.110 |
Why?
| Cytotoxicity, Immunologic | 2 | 2005 | 54 | 0.110 |
Why?
| Protein Binding | 2 | 2005 | 660 | 0.100 |
Why?
| Mutation | 1 | 2018 | 1294 | 0.100 |
Why?
| Immunity, Cellular | 2 | 2003 | 69 | 0.100 |
Why?
| Mice, Nude | 2 | 2004 | 252 | 0.100 |
Why?
| C-Reactive Protein | 1 | 2023 | 142 | 0.100 |
Why?
| Lymphocyte Activation | 3 | 2001 | 172 | 0.100 |
Why?
| Kinetics | 2 | 2005 | 623 | 0.100 |
Why?
| Injections, Intramuscular | 2 | 2003 | 54 | 0.100 |
Why?
| Interleukin-6 | 1 | 2023 | 264 | 0.100 |
Why?
| Binding Sites | 2 | 2003 | 374 | 0.100 |
Why?
| Prognosis | 3 | 2020 | 1942 | 0.100 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2023 | 388 | 0.090 |
Why?
| Lung | 1 | 2014 | 486 | 0.090 |
Why?
| Microscopy, Phase-Contrast | 1 | 2010 | 11 | 0.090 |
Why?
| Body Weight | 1 | 2023 | 513 | 0.090 |
Why?
| B-Lymphocytes | 2 | 2002 | 170 | 0.090 |
Why?
| DNA Methylation | 1 | 2015 | 548 | 0.090 |
Why?
| Transfection | 3 | 2007 | 354 | 0.090 |
Why?
| Substrate Specificity | 1 | 2010 | 194 | 0.090 |
Why?
| Antigens, CD | 2 | 2003 | 219 | 0.090 |
Why?
| Membrane Glycoproteins | 2 | 2003 | 240 | 0.090 |
Why?
| Actins | 1 | 2010 | 118 | 0.090 |
Why?
| Antibodies, Catalytic | 1 | 2009 | 1 | 0.090 |
Why?
| Receptors, CCR5 | 1 | 2009 | 6 | 0.090 |
Why?
| Dose-Response Relationship, Drug | 2 | 2005 | 1376 | 0.090 |
Why?
| Neoplasm Invasiveness | 1 | 2010 | 267 | 0.090 |
Why?
| Cells, Cultured | 2 | 2003 | 1573 | 0.080 |
Why?
| Time Factors | 2 | 2005 | 2903 | 0.080 |
Why?
| Killer Cells, Natural | 1 | 2009 | 95 | 0.080 |
Why?
| Male | 3 | 2023 | 25241 | 0.070 |
Why?
| Fucosyltransferases | 1 | 2007 | 5 | 0.070 |
Why?
| Glycosaminoglycans | 1 | 2007 | 19 | 0.070 |
Why?
| Molecular Biology | 1 | 2007 | 25 | 0.070 |
Why?
| Binding Sites, Antibody | 1 | 2006 | 15 | 0.070 |
Why?
| Amino Acid Motifs | 1 | 2006 | 56 | 0.070 |
Why?
| Cricetulus | 1 | 2006 | 97 | 0.070 |
Why?
| Rats | 1 | 2023 | 3305 | 0.070 |
Why?
| Heparin | 1 | 2007 | 92 | 0.070 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2006 | 74 | 0.070 |
Why?
| E-Selectin | 1 | 2005 | 15 | 0.070 |
Why?
| Cell Membrane | 1 | 2007 | 248 | 0.070 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2006 | 211 | 0.070 |
Why?
| Hydrocarbons | 1 | 2005 | 5 | 0.070 |
Why?
| Phosphorylcholine | 1 | 2005 | 13 | 0.070 |
Why?
| Densitometry | 1 | 2005 | 11 | 0.060 |
Why?
| Mannose | 1 | 2005 | 16 | 0.060 |
Why?
| Cyclophosphamide | 1 | 2006 | 165 | 0.060 |
Why?
| Wheat Germ Agglutinins | 1 | 2005 | 3 | 0.060 |
Why?
| Methane | 1 | 2005 | 7 | 0.060 |
Why?
| Surface Plasmon Resonance | 1 | 2005 | 22 | 0.060 |
Why?
| Bone Marrow Cells | 1 | 2006 | 191 | 0.060 |
Why?
| Biosensing Techniques | 1 | 2005 | 25 | 0.060 |
Why?
| Growth Inhibitors | 1 | 2005 | 27 | 0.060 |
Why?
| Calcium | 1 | 2007 | 396 | 0.060 |
Why?
| Glycolysis | 1 | 2005 | 70 | 0.060 |
Why?
| Genetic Variation | 1 | 2006 | 213 | 0.060 |
Why?
| Immunoglobulins | 1 | 2005 | 79 | 0.060 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 411 | 0.060 |
Why?
| Antigen Presentation | 1 | 2004 | 25 | 0.060 |
Why?
| Endothelial Cells | 1 | 2006 | 269 | 0.060 |
Why?
| Bone Neoplasms | 1 | 2006 | 179 | 0.060 |
Why?
| Treatment Outcome | 1 | 2014 | 5141 | 0.060 |
Why?
| Cytosol | 1 | 2004 | 82 | 0.060 |
Why?
| Middle Aged | 2 | 2020 | 12069 | 0.060 |
Why?
| Immunoglobulin Constant Regions | 1 | 2003 | 2 | 0.060 |
Why?
| Plasmids | 2 | 2003 | 161 | 0.060 |
Why?
| Recombinant Proteins | 1 | 2005 | 486 | 0.060 |
Why?
| Antibodies, Viral | 1 | 2003 | 88 | 0.060 |
Why?
| Histocompatibility Antigens Class II | 1 | 2003 | 37 | 0.060 |
Why?
| Immunoglobulin M | 1 | 2003 | 52 | 0.050 |
Why?
| Bacterial Capsules | 1 | 2003 | 18 | 0.050 |
Why?
| Th1 Cells | 1 | 2003 | 52 | 0.050 |
Why?
| DNA, Neoplasm | 1 | 2003 | 147 | 0.050 |
Why?
| Carbohydrate Metabolism | 1 | 2002 | 26 | 0.050 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2002 | 19 | 0.050 |
Why?
| Models, Chemical | 1 | 2002 | 66 | 0.050 |
Why?
| L-Selectin | 1 | 2001 | 7 | 0.050 |
Why?
| Calorimetry | 1 | 2001 | 6 | 0.050 |
Why?
| Carbohydrate Sequence | 1 | 2001 | 11 | 0.050 |
Why?
| Epitope Mapping | 1 | 2001 | 6 | 0.050 |
Why?
| Thermodynamics | 1 | 2001 | 34 | 0.050 |
Why?
| Binding, Competitive | 1 | 2001 | 94 | 0.050 |
Why?
| Mice, Inbred CBA | 1 | 2001 | 35 | 0.050 |
Why?
| Protein Structure, Secondary | 1 | 2001 | 72 | 0.050 |
Why?
| Gene Expression Profiling | 1 | 2006 | 1032 | 0.050 |
Why?
| Sequence Homology, Amino Acid | 1 | 2001 | 144 | 0.050 |
Why?
| Protein Conformation | 1 | 2001 | 166 | 0.050 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 1 | 2000 | 12 | 0.050 |
Why?
| Injections, Intraperitoneal | 1 | 2000 | 54 | 0.050 |
Why?
| Colchicum | 1 | 2020 | 4 | 0.050 |
Why?
| Inhibitory Concentration 50 | 1 | 2020 | 76 | 0.040 |
Why?
| Models, Molecular | 1 | 2001 | 338 | 0.040 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2020 | 136 | 0.040 |
Why?
| Child, Preschool | 1 | 2008 | 3871 | 0.040 |
Why?
| Wnt Signaling Pathway | 1 | 2020 | 92 | 0.040 |
Why?
| H-2 Antigens | 1 | 1999 | 4 | 0.040 |
Why?
| Receptors, Estrogen | 1 | 2020 | 130 | 0.040 |
Why?
| Transformation, Genetic | 1 | 1998 | 16 | 0.040 |
Why?
| Clostridium | 1 | 1998 | 15 | 0.040 |
Why?
| Glycoside Hydrolases | 1 | 1998 | 17 | 0.040 |
Why?
| Cell Survival | 1 | 2020 | 600 | 0.040 |
Why?
| Plants | 1 | 1998 | 27 | 0.040 |
Why?
| Genes, Reporter | 1 | 1998 | 89 | 0.040 |
Why?
| Models, Biological | 1 | 2001 | 727 | 0.040 |
Why?
| Survival Rate | 1 | 2020 | 894 | 0.040 |
Why?
| Adolescent | 1 | 2008 | 6356 | 0.040 |
Why?
| Retrospective Studies | 1 | 2008 | 6108 | 0.030 |
Why?
| Child | 1 | 2008 | 6847 | 0.030 |
Why?
| CpG Islands | 1 | 2015 | 108 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 825 | 0.030 |
Why?
| RNA Interference | 1 | 2011 | 179 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2011 | 215 | 0.020 |
Why?
| Simian virus 40 | 1 | 2003 | 12 | 0.010 |
Why?
| Lymphocyte Subsets | 1 | 2003 | 13 | 0.010 |
Why?
| Immunoglobulin Variable Region | 1 | 2003 | 13 | 0.010 |
Why?
| Mutagenesis, Site-Directed | 1 | 2003 | 99 | 0.010 |
Why?
| Sequence Deletion | 1 | 2003 | 66 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2003 | 253 | 0.010 |
Why?
| Recombinant Fusion Proteins | 1 | 2003 | 181 | 0.010 |
Why?
| Down-Regulation | 1 | 2003 | 348 | 0.010 |
Why?
| Up-Regulation | 1 | 2003 | 452 | 0.010 |
Why?
| Radiation Chimera | 1 | 1999 | 3 | 0.010 |
Why?
| HIV Envelope Protein gp160 | 1 | 1999 | 2 | 0.010 |
Why?
| beta 2-Microglobulin | 1 | 1999 | 38 | 0.010 |
Why?
| Protein Engineering | 1 | 1999 | 18 | 0.010 |
Why?
| Plants, Toxic | 1 | 1998 | 10 | 0.010 |
Why?
| Enzyme Stability | 1 | 1998 | 20 | 0.010 |
Why?
| Plants, Genetically Modified | 1 | 1998 | 22 | 0.010 |
Why?
| Stem Cells | 1 | 1999 | 171 | 0.010 |
Why?
| Hot Temperature | 1 | 1998 | 207 | 0.010 |
Why?
| Signal Transduction | 1 | 2003 | 1618 | 0.010 |
Why?
| Mice, Knockout | 1 | 1999 | 841 | 0.010 |
Why?
| Mice, Inbred C57BL | 1 | 1999 | 1816 | 0.010 |
Why?
| Muscle, Skeletal | 1 | 1999 | 750 | 0.010 |
Why?
|
|
Karbassi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|